25.09.2013 • NewscancerVaccinesMerck

Merck KGaA to Continue Testing Cancer Vaccine

Germany's Merck KGaA said it would start a new study testing its experimental lung cancer vaccine Stimuvax, which fell through in a previous late-stage trial.

Merck said it would test the drug, which it licensed from U.S. biotech firm Oncothyreon, on patients with locally advanced Stage III non-small cell lung cancer (NSCLC), which cannot be surgically removed.

Stimuvax, also known as Tecemotide, failed to improve survival in a pivotal study in December, dealing a blow to the company and the high-risk field of using vaccines to fight tumours.

Merck said that data from an analysis of a predefined patient subgroup in this trial, however, showed some promise.

 

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.